Whole genome and global expression profiling of Dupuytren's disease: Systematic review of current findings and future perspectives

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1440-1447

  Shih, B ^a   Watson, S ^b   Bayat, Ardeshir ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; INTEGRIN; MESSENGER RNA; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

DOWN REGULATION; DUPUYTREN CONTRACTURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; UPREGULATION; VALIDATION PROCESS; WNT SIGNALING PATHWAY;

DUPUYTREN CONTRACTURE; GENE EXPRESSION PROFILING; GENOME; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84864885070     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201295     Document Type: Review

References (96)

1. Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol 2010;6:715-26.
2. Hindocha S, Stanley JK, Watson S, et al. Dupuytren's diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am 2006;31:1626-34. (Pubitemid 44834570)
3. Thurston AJ. Dupuytren's disease. J Bone Joint Surg Br 2003;85:469-77. (Pubitemid 36621959)
4. Burge P. Genetics of Dupuytren's disease. Hand Clin 1999;15:63-71. (Pubitemid 29066105)
5. Forsman M, Pääkkönen V, Tjäderhane L, et al. The expression of myoglobin and ROR2 protein in Dupuytren's disease. J Surg Res 2008;146:271-5. (Pubitemid 351492554)
6. Lee LC, Zhang AY, Chong AK, et al. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am 2006;31:211-18. (Pubitemid 43227270)
7. Pan D, Watson HK, Swigart C, et al. Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg 2003;50:618-22. (Pubitemid 36666699)
8. Qian A, Meals RA, Rajfer J, et al. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004;64:399-404. (Pubitemid 39092491)
9. Rehman S, Salway F, Stanley JK, et al. Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg Am 2008;33:359-72. (Pubitemid 351384747)
10. Satish L, LaFramboise WA, O'Gorman DB, et al. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's contracture. BMC Med Genomics 2008;1:10.
11. Vi L, Feng L, Zhu RD, et al. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp Cell Res 2009;315:3574-86.
12. Zhang AY, Fong KD, Pham H, et al. Gene expression analysis of Dupuytren's disease: the role of TGF-beta2. J Hand Surg Eur Vol 2008;33:783-90.
13. Mosakhani N, Guled M, Lahti L, et al. Unique microRNA profile in Dupuytren's contracture supports deregulation of β-catenin pathway. Mod Pathol 2010;23:1544-52.
14. Shih B, Wijeratne D, Armstrong DJ, et al. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am 2009;34:124-36.
15. Augoff K, Ratajczak K, Gosk J, et al. Gelatinase A activity in Dupuytren's disease. J Hand Surg Am 2006;31:1635-9. (Pubitemid 44828299)
16. Ulrich D, Ulrich F, Piatkowski A, et al. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease. Arch Orthop Trauma Surg 2009;129:1453-9.
17. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31. (Pubitemid 38868508)
18. Kapushesky M, Emam I, Holloway E, et al. Gene expression atlas at the European Bioinformatics Institute. Nucleic Acids Res 2010;38:D690-8.
19. Guo Y, Xiao P, Lei S, et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai) 2008;40:426-36. (Pubitemid 351704046)
20. Pascal LE, True LD, Campbell DS, et al. Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics 2008;9:246.
21. Kraljevic Pavelic S, Sedic M, Hock K, et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 2009;217:524-33.
22. O'Gorman D, Howard JC, Varallo VM, et al. Identification of protein biomarkers in Dupuytren's contracture using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Clin Invest Med 2006;29:136-45. (Pubitemid 43927072)
23. Krause C, Kloen P, Ten Dijke P. Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair 2011;4:14.
24. Hamilton DW. Functional role of periostin in development and wound repair: implications for connective tissue disease. J Cell Commun Signal 2008;2:9-17.
25. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 2009;66:2219-30.
26. Badalamente MA, Sampson SP, Hurst LC, et al. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am 1996;21:210-5. (Pubitemid 26099450)
27. Howard JC, Varallo VM, Ross DC, et al. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res 2004;117:232-8. (Pubitemid 38393648)
28. Berndt A, Kosmehl H, Katenkamp D, et al. Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994;62:55-8. (Pubitemid 24215140)
29. Magro G, Fraggetta F, Travali S, et al. Immunohistochemical expression and distribution of alpha2beta1, alpha6beta1, alpha5beta1 integrins and their extracellular ligands, type IV collagen, laminin and fibronectin in palmar fibromatosis. Gen Diagn Pathol 1997;143:203-8. (Pubitemid 28040865)
30. Forsman M, Kallioinen L, Kallioinen M, et al. Dupuytren's contracture; increased cellularity - proliferation, is there equality? Scand J Surg 2005;94:71-5. (Pubitemid 40528431)
31. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase Clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009;361:968-79.
32. Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008;20:495-501.
33. Brickley-Parsons D, Glimcher MJ, Smith RJ, et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am 1981;63:787-97. (Pubitemid 11127664)
34. Murrell GA, Francis MJ, Bromley L. The collagen changes of Dupuytren's contracture. J Hand Surg Br 1991;16:263-6.
35. Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol 2005;53:430-42. (Pubitemid 41112079)
36. Birk DE, Fitch JM, Babiarz JP, et al. Collagen type I and type V are present in the same fibril in the avian corneal stroma. J Cell Biol 1988;106:999-1008. (Pubitemid 18090000)
37. Wenstrup RJ, Florer JB, Cole WG, et al. Reduced type I collagen utilization: a pathogenic mechanism in COL5A1 haplo-insufficient Ehlers-Danlos syndrome. J Cell Biochem 2004;92:113-24.
38. Tomasek JJ, Schultz RJ, Haaksma CJ. Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J Bone Joint Surg Am 1987;69:1400-7. (Pubitemid 18057150)
39. Kaur S, Forsman M, Ryhänen J, et al. No gene copy number changes in Dupuytren's contracture by array comparative genomic hybridization. Cancer Genet Cytogenet 2008;183:6-8. (Pubitemid 351637608)
40. Shih B, Tassabehji M, Watson JS, et al. DNA copy number variations at chromosome 7p14.1 and chromosome 14q11.2 are associated with Dupuytren's disease: potential role for MMP and Wnt signaling pathway. Plast Reconstr Surg 2012;129:921-32.
41. Shih BB, Tassabehji M, Watson JS, et al. Genome-wide high-resolution screening in Dupuytren's disease reveals common regions of DNA copy number alterations. J Hand Surg Am 2010;35:1172-1183.e7.
42. Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet 2005;68:424-9. (Pubitemid 41535966)
43. Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren's disease. N Engl J Med 2011;365:307-17.
44. Ojwang JO, Adrianto I, Gray-McGuire C, et al. Genome-wide association scan of Dupuytren's disease. J Hand Surg Am 2010;35:2039-45.
45. Li X, Iomini C, Hyink D, et al. PRKX critically regulates endothelial cell proliferation, migration, and vascular-like structure formation. Dev Biol 2011;356:475-85.
46. Gonzalez AM, Buscaglia M, Fox R, et al. Basic fibroblast growth factor in Dupuytren's contracture. Am J Pathol 1992;141:661-71.
47. Ly L, Winship I. X-linked recessive polyfibromatosis manifesting with spontaneous keloid scars and Dupuytren's contracture. Australas J Dermatol 2011; article first published online: 7 MAR 2011. DOI: 10.1111/j.1440-0960.2011. 00740.x.
48. Kataoka K, Fujiwara KT, Noda M, et al. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol Cell Biol 1994;14:7581-91. (Pubitemid 24326424)
49. Sieweke MH, Tekotte H, Frampton J, et al. MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation. Cell 1996;85:49-60. (Pubitemid 26116806)
50. Drake J, Shearwood AM, White J, et al. Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours. Eur J Gynaecol Oncol 2009;30:133-41.
51. Matsushima K, Suyama T, Takenaka C, et al. Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury. Tissue Eng Part A 2010;16:3329-41.
52. Muley A, Majumder S, Kolluru GK, et al. Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol 2010;176:1505-16.
53. Thomas LF, Saito T, Sætrom P. Inferring causative variants in microRNA target sites. Nucleic Acids Res 2011;39:e109.
54. Landi D, Gemignani F, Naccarati A, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29:579-84. (Pubitemid 351404875)
55. Attisano L, Labbé E. TGFbeta and Wnt pathway cross-talk. Cancer Metastasis Rev 2004;23:53-61.
56. Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009;19:71-88.
57. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105.
58. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 2004;6:358-65. (Pubitemid 38584826)
59. Schambony A, Kunz M, Gradl D. Cross-regulation of Wnt signaling and cell adhesion. Differentiation 2004;72:307-18. (Pubitemid 41702123)
60. Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000;2:170-5. (Pubitemid 32223581)
61. Lal H, Verma SK, Smith M, et al. Stretch-induced MAP kinase activation in cardiac myocytes: differential regulation through beta1-integrin and focal adhesion kinase. J Mol Cell Cardiol 2007;43:137-47. (Pubitemid 47069384)
62. Kanbe K, Inoue K, Inoue Y, et al. Inducement of mitogen-activated protein kinases in frozen shoulders. J Orthop Sci 2009;14:56-61.
63. Magro G, Lanzafame S, Micali G. Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren's disease. Acta Histochem 1995;97:229-33.
64. Quaglino D, Bergamini G, Croce A, et al. Cell behavior and cell-matrix interactions of human palmar aponeurotic cells in vitro. J Cell Physiol 1997;173:415-22. (Pubitemid 27481099)
65. Satish L, Gallo PH, Baratz ME, et al. Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts. BMC Musculoskelet Disord 2011;12:113.
66. Howard JC, Varallo VM, Ross DC, et al. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003;4:16.
67. Halliday NL, Rayan GM, Zardi L, et al. Distribution of ED-A and ED-B containing fibronectin isoforms in Dupuytren's disease. J Hand Surg Am 1994;19:428-34. (Pubitemid 24164551)
68. Berndt A, Kosmehl H, Mandel U, et al. TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995;27:1014-20. (Pubitemid 26040135)
69. Merlo G, Ambroggio GP, Mosca A, et al. Possible role of plasminogen activator content of the palmar nodules in recurrence of Dupuytren's contracture. J Hand Surg Am 1987;12:1017-19. (Pubitemid 18001285)
70. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004;5:329-39. (Pubitemid 38482069)
71. Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease. Cell Signal 2011;23:1515-27.
72. Kiely PA, Sant A, O'Connor R. RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J Biol Chem 2002;277:22581-9. (Pubitemid 34967235)
73. Bisson MA, McGrouther DA, Mudera V, et al. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg Br 2003;28:351-6. (Pubitemid 36896174)
74. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999;1:1349-65.
75. Bayat A, Watson JS, Stanley JK, et al. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast Reconstr Surg 2003;111:2133-9. (Pubitemid 36676785)
76. Bayat A, Stanley JK, Watson JS, et al. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. Br J Plast Surg 2003;56:328-33. (Pubitemid 36927264)
77. Battegay EJ, Raines EW, Seifert RA, et al. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;63:515-24.
78. Badalamente MA, Hurst LC, Grandia SK, et al. Platelet-derived growth factor in Dupuytren's disease. J Hand Surg Am 1992;17:317-23.
79. Sgonc R, Wick G. Pro- and anti-fibrotic effects of TGF-beta in scleroderma. Rheumatology (Oxford) 2008;47(Suppl. 5):v5-7.
80. Prelog M, Scheidegger P, Peter S, et al. Diminished transforming growth factor beta2 production leads to increased expression of a profibrotic procollagen alpha2 type I messenger RNA variant in embryonic fibroblasts of UCD-200 chickens, a model for systemic sclerosis. Arthritis Rheum 2005;52:1804-11. (Pubitemid 40852889)
81. Smith P, Mosiello G, Deluca L, et al. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 1999;82:319-23. (Pubitemid 29394140)
82. Varallo VM, Gan BS, Seney S, et al. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003;22:3680-4. (Pubitemid 36760730)
83. Degreef I, De Smet L, Sciot R, et al. Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence. Clin Orthop Relat Res 2009;467:838-45.
84. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)
85. O'Gorman DB, Wu Y, Seney S, et al. Wnt expression is not correlated with betacatenin dysregulation in Dupuytren's Disease. J Negat Results Biomed 2006;5:13.
86. Gauger KJ, Chenausky KL, Murray ME, et al. SFRP1 reduction results in an increased sensitivity to TGF-β signaling. BMC Cancer 2011;11:59.
87. Degreef I, De Smet L, Sciot R, et al. Immunohistochemical evidence for Zic1 coexpression with beta-catenin in the myofibroblast of Dupuytren disease. Scand J Plast Reconstr Surg Hand Surg 2009;43:36-40.
88. Maeda K, Kobayashi Y, Udagawa N, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012; 18:405-12.
89. Edris B, Espinosa I, Mühlenberg T, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 2012; 227:223-33.
90. Johnston P, Chojnowski AJ, Davidson RK, et al. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg Am 2007;32:343-51. (Pubitemid 46343688)
91. Yamagata K, Li X, Ikegaki S, et al. Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression. J Biol Chem 2012;287:1588-99.
92. Schweizer L, Rizzo CA, Spires TE, et al. The androgen receptor can signal through Wnt/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 2008;9:4.
93. Pagnotta A, Specchia N, Greco F. Androgen receptors in Dupuytren's contracture. J Orthop Res 2002;20:163-8. (Pubitemid 34071436)
94. Bayat A. Connective tissue diseases: unpicking Dupruyten disease etiology - is Wnt the way? Nat Rev Rheumatol 2012;8:5-6.
95. Rehman S, Goodacre R, Day PJ, et al. Dupuytren's: a systems biology disease. Arthritis Res Ther 2011;13:238.
96. Johnston P, Larson D, Clark IM, et al. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am 2008;33:1160-7.